Vitura Health Raises $5.1 Million in Strategic Capital Placement

Highlights:

• $5.17 Million Capital Raise: Vitura Health Limited (ASX: VIT) secured funding from Professor Khalil (Charlie) Shahin AO, with 74.8 million shares issued at $0.06912 per share.
• Strategic Acquisition Funding: The capital will support the $4 million initial cash payment for the acquisition of Candor Medical, with the remainder allocated for future expansion.
• Investor Confidence: Professor Shahin’s investment underscores Vitura’s growth potential, with an anticipated boost in revenue, EBITDA, and earnings per share in FY2025.

Investment from Professor Khalil (Charlie) Shahin AO

Melbourne, Australia – Vitura Health Limited (ASX: VIT) has successfully secured a $5.17 million capital injection through a Share Subscription Agreement with AFO Investments Pty Ltd, as Trustee for the AFO Investment Trust. The investment, led by South Australian entrepreneur Professor Khalil (Charlie) Shahin

AO, strengthens Vitura’s financial position and aligns with its strategic expansion plans.

Professor Shahin, Managing Director of Peregrine Corporation, is a prominent investor and business leader with an extensive track record in corporate growth. Having co-founded Peregrine Corporation in 1984, he has played a pivotal role in transforming it into one of Australia's largest privately owned businesses. The company previously owned the OTR Group, which was sold to Viva Energy in 2023 for $1.15 billion.

Share Issuance and Pricing Details

As part of the agreement, 74,814,757 ordinary shares have been issued to AFO at $0.06912 per share, reflecting a 10% discount to Vitura’s five-day volume-weighted average price on 31 January 2025. At the time of writing, the placement represents 11.4% of the company’s total issued capital. Notably, no additional fees were incurred for the transaction, ensuring an efficient capital raise for Vitura.

Utilization of Funds and Future Growth Plans

The capital raised will primarily support the $4 million initial cash payment for Vitura’s acquisition of Candor Medical, announced on 12 February 2025. The remaining funds will contribute to Vitura’s broader growth initiatives, reinforcing its position as a leader in digital healthcare. The company anticipates a significant boost in revenue and EBITDA in FY2025, with a corresponding increase in earnings per share post-placement.

Strategic Endorsement and Market Impact

Vitura Chair Robert Iervasi welcomed Professor Shahin’s investment, highlighting it as a validation of the company’s growth strategy. Shahin expressed enthusiasm about his new role as a major shareholder, emphasizing his confidence in Vitura’s future prospects.

Following this announcement, Vitura’s trading halt has been lifted, signaling renewed investor interest in the company’s trajectory.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com